---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031701"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:04:34.233228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials

## Summary
- Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.
- R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.
- Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.
- Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.
- Completed $144M public offering in February 2026; appointed new CEO and two board members.

## SEC filing metadata
- accession: 0001628280-26-031701
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/0001628280-26-031701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031701
- JSON: https://secwatch.observer/filing/0001628280-26-031701.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.